Form 4: Corvus Pharmaceuticals Director Peter Thompson Granted 15,000 Stock Options

Corvus Pharmaceuticals, Inc. (CRVS) disclosed that Director and 10% Owner Peter A. Thompson was granted 15,000 stock options with an exercise price of $4.24, vesting over one year or by the 2026 Annual Meeting.

Summary

• Peter A. Thompson, a Director and 10% Owner of Corvus Pharmaceuticals, Inc. (CRVS), was granted 15,000 stock options.
• The options have an exercise price of $4.24 per share.
• The options vest 100% on the earlier of the first anniversary of the grant date or the date of the Issuer's 2026 Annual Meeting of stockholders, contingent on continuous service as a director.
• The expiration date for these stock options is June 12, 2035.
• Following this transaction, Peter A. Thompson directly beneficially owns 15,000 derivative securities (stock options).
• Pursuant to an agreement, Mr. Thompson is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will then provide them to OrbiMed Private Investments V, LP.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard compensation event that aligns the interests of a key director and significant shareholder with the company's performance, without indicating any immediate negative implications.

Positives

• The grant of stock options to a director and significant owner aligns management's interests with shareholder value creation, as the options gain value if the stock price increases.

Risks

• The obligation for the reporting person to transfer the securities or their economic benefit to OrbiMed entities introduces complexity regarding the direct beneficial ownership and control of these shares by the director.

Future Outlook

The stock options are set to vest 100% on the earlier of the first anniversary of the grant date or the date of the 2026 Annual Meeting, contingent on Peter A. Thompson's continuous service as a director, indicating an expectation of continued involvement.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a form of compensation and a mechanism to align the interests of directors with the long-term performance of the company.

Corporate Governance

Related Party Transactions

• Peter A. Thompson is obligated, pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, to transfer any securities issued under the stock options or their economic benefit to these entities, which will then provide them to OrbiMed Private Investments V, LP. This indicates a pre-existing arrangement with entities related to OrbiMed, a significant investor.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with company performance.
• Employees: No direct impact mentioned for general employees.
• Director (Peter A. Thompson): Receives equity-based compensation, subject to vesting conditions and a pre-existing transfer agreement with OrbiMed entities.

Next Steps

• The stock options will vest 100% on the earlier of June 12, 2026 (first anniversary of grant date) or the date of the 2026 Annual Meeting of stockholders, assuming continuous service.
• Upon vesting, the options will become exercisable, allowing Peter A. Thompson to purchase 15,000 shares of Common Stock at the exercise price of $4.24.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Stock Option, Form 4, Insider Transaction, Director Compensation, OrbiMed, Equity Grant